摘要

BACKGROUND:Recent literature describing the effect of gastric acid suppression on levothyroxine absorption has been inconsistent. Also, ezetimibe, a lipid-lowering compound that inhibits intestinal absorption of cholesterol, may interfere with levothyroxine absorption. The objective of this study was to measure changes in levothyroxine absorption before and after famotidine, esomeprazole or single-dose ezetimibe."
METHODS:We conducted levothyroxine absorption testing on 30 healthy volunteers, excluding those with thyroid disease. Subjects were randomized to receive one of three regimens: 1 week of either famotidine or esomeprazole, or a single dose of ezetimibe administered simultaneously with levothyroxine (n = 10 in each group). Baseline levothyroxine absorption testing was performed on all subjects using 600 mcg of Synthroid with thyroid hormone levels checked at 0, 2, 4, 6, and 8 hours after administration, and then repeated 6 weeks later, after administration of one of the three study drug regimens. The area under the curve (AUC) over 8 hours for serum thyroxine (T4), triiodothyronine (T3), and free T4 index, and the mean peak hormone levels achieved during levothyroxine absorption testing at baseline and following administration of one of the three study medications were compared using paired t-tests.
RESULTS:Peak mean hormone levels and AUCs of T4, T3, and free T4 index during absorption testing before and after each of three study medications did not differ. Results for differences before and after study medication did not reach significance even when using the subtractive correction method of AUC calculation.
CONCLUSIONS:No differences were noted in levothyroxine absorption after gastric acid suppression with 1 week of famotidine or esomeprazole. A simultaneously administered dose of ezetimibe did not significantly change levothyroxine absorption.

译文

背景: 最近描述胃酸抑制对左旋甲状腺素吸收的影响的文献并不一致。此外,依折麦布,一种抑制胆固醇肠吸收的降脂化合物,可能会干扰左旋甲状腺素的吸收。本研究的目的是测量法莫替丁、埃索美拉唑或单剂量依折麦布前后左旋甲状腺素吸收的变化。
方法: 我们对 30 名健康志愿者进行了左旋甲状腺素吸收测试,不包括甲状腺疾病患者。受试者随机接受三种方案中的一种: 法莫替丁或埃索美拉唑 1 周,或单剂量依折麦布与左旋甲状腺素同时给药 (每组 n = 10)。基线左旋甲状腺素吸收测试是在所有受试者身上进行的,使用 600 微克的合成甲状腺激素,并在给药后 0 、 2 、 4 、 6 和 8 小时检查甲状腺激素水平。然后 6 周后,在三种研究药物方案中的一种给药后重复。血清甲状腺素 (T4) 、三碘甲状腺原氨酸 (T3) 和游离 T4 指数 8 小时的曲线下面积 (AUC), 使用配对 t检验比较基线左旋甲状腺素吸收测试和三种研究药物之一给药后达到的平均峰值激素水平。
结果: 在三种研究药物前后的吸收测试中,峰值平均激素水平和 T4 、 T3 和游离 T4 指数的 auc 没有差异。结果对于研究用药前后的差异,即使使用 AUC 计算的减法校正方法,也没有达到显著性。
结论: 法莫替丁或埃索美拉唑抑制胃酸 1 周后左旋甲状腺素吸收无差异。同时给药剂量的依折麦布不会显著改变左旋甲状腺素的吸收。

Famotidine

消化 H2受体阻滞剂 药物
概述  :  

法莫替丁为第3代H2受体阻滞剂。主要用于治疗各种消化性溃疡和卓-艾综合征。由于其作用强、特异性高、耐受性好、起效快、毒性和副作用小等特点,迅速取代雷尼替丁和西咪替丁而成为抗消化性溃疡的最重要的药物,也是世界上最畅销的药物之一。法莫替丁制剂研究近年来取得很大的成果,其制剂品种越来越多。目前有片剂、胶囊剂、分散片等十多种。   药理 1)药效学:本药为高效、长效的呱基噻唑类H2受体阻滞药,具有对H2受体亲和力高的特点,其作用

Famotidine  英/feɪ'mɒtaɪdɪn/  美 /feɪ'mɒtaɪdɪn/

释    义   n.法莫替丁

例    句   To optimize dissolution determination of compound famotidine dispersibletablets. 建立复方法莫替丁分散片的溶出度测定方法.

请扫描右侧二维码,免费查看词汇专业知识背景